Purdue Pharma informed a New York bankruptcy judge on Tuesday about its plans for a two-month “high-speed, high-stakes” attempt to draft a new Chapter 11 plan. This development follows the U.S. Supreme Court’s recent decision to invalidate the company’s previous plan. The rejected plan was a cornerstone for Purdue’s attempts to resolve its legal troubles arising from the opioid crisis.
The pharmaceutical company aims to introduce this revised plan swiftly to replace the invalidated Chapter 11 proposal. Beyond merely drafting and submitting this new plan, Purdue also signals its readiness to engage in subsequent litigation against its former owning family. This high-stakes legal maneuvering could be pivotal in determining the future liabilities and financial structure of Purdue Pharma amid ongoing scrutiny.
For further details on this ongoing legal battle, visit the original article.